Literature DB >> 23359301

IL-6-positive classical Hodgkin's lymphoma co-occurring with plasma cell type of Castleman's disease: report of a case.

Akihito Momoi1, Masaru Kojima, Takeshi Sakai, Junya Ajiro, Noriatsu Isahai, Kouichi Nagai, Sadao Aoki.   

Abstract

We present a case of classical Hodgkin's lymphoma (HL) co-occurring with histological features of Castleman's disease (CD). A 25-year-old man presented with left supraclavicular and axillary lymph node swelling and mediastinal mass. Using an initial biopsy specimen from left axillary lymph node, a tentative diagnosis of multicentric CD of plasma cell type was made. The serum level of interleukin-6 (IL-6) was elevated. The patient was treated with immunosuppressive therapy containing tocilizumab (TCZ). Shrinkage of mediastinal mass and axillary lymph nodes was seen; however, swelling of his left axillary lymph nodes reemerged, even after therapy with TCZ. A second left axillary lymph node biopsy was performed and a diagnosis of nodular sclerosis of classical HL without histologic features of CD was made. The initial biopsy specimen was re-examined, and scattered CD30+ Hodgkin/Reed-Sternberg cells were found in the interfollicular area. Interestingly, Hodgkin/Reed-Sternberg cells and surrounding reactive cells in both lymph nodes were stained with anti-IL-6 antibody. We emphasize that biopsy specimens with HL involvement may also have histologic features reminiscent of those seen in CD. To our knowledge, this is the first report to provide a detailed description of this pathology, including a survey of IL-6 and clinical course upon treatment with TCZ.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23359301     DOI: 10.1007/s12185-013-1262-7

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  17 in total

1.  Hodgkin's and Castleman's disease in a patient with systemic mastocytosis.

Authors:  P Saletti; M Ghielmini; G Scali; E Pedrinis; M Guéneau; F Cavalli
Journal:  Ann Hematol       Date:  1999-02       Impact factor: 3.673

2.  Interleukin-6, but not interleukin-4, is expressed by Reed-Sternberg cells in Hodgkin's disease with or without histologic features of Castleman's disease.

Authors:  S M Hsu; S S Xie; P L Hsu; J A Waldron
Journal:  Am J Pathol       Date:  1992-07       Impact factor: 4.307

3.  Idiopathic multicentric Castleman's disease. A clinicopathologic and immunohistochemical study of five cases.

Authors:  Masaru Kojima; Shigeo Nakamura; Masafumi Nishikawa; Hideaki Itoh; Shuichi Miyawaki; Nobuhide Masawa
Journal:  Pathol Res Pract       Date:  2005       Impact factor: 3.250

4.  Hodgkin's disease in a patient with Castleman's disease.

Authors:  E J McAloon
Journal:  N Engl J Med       Date:  1985-09-19       Impact factor: 91.245

5.  Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte.

Authors:  René-Olivier Casasnovas; Nicolas Mounier; Pauline Brice; Marine Divine; Franck Morschhauser; Jean Gabarre; Jean-Yves Blay; Laurent Voillat; Pierre Lederlin; Aspasia Stamatoullas; Jacques Bienvenu; Michel Guiguet; Liliane Intrator; Monique Grandjean; Josette Brière; Christophe Ferme; Gilles Salles
Journal:  J Clin Oncol       Date:  2007-03-26       Impact factor: 44.544

Review 6.  Castleman's disease and lymphoma: report of eight cases in HIV-negative patients and literature review.

Authors:  Claire Larroche; Patrice Cacoub; Jean Soulier; Eric Oksenhendler; Jean-Pierre Clauvel; Jean-Charles Piette; Martine Raphael
Journal:  Am J Hematol       Date:  2002-02       Impact factor: 10.047

7.  Three patients with both Hodgkin's lymphoma and Castleman's disease: Clinicopathologic correlations and lack of association with HHV-8.

Authors:  Saadiya Haque; Robert van Kirk
Journal:  Indian J Med Paediatr Oncol       Date:  2009-04

8.  Interfollicular Hodgkin's disease.

Authors:  R S Doggett; T V Colby; R F Dorfman
Journal:  Am J Surg Pathol       Date:  1983-03       Impact factor: 6.394

Review 9.  Coexistence of Hodgkin's disease and giant lymph node hyperplasia of the plasma-cell type (Castleman's disease).

Authors:  F A Abdel-Reheim; W Koss; E S Rappaport; D A Arber
Journal:  Arch Pathol Lab Med       Date:  1996-01       Impact factor: 5.534

10.  IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways.

Authors:  Liang Zhou; Ivaylo I Ivanov; Rosanne Spolski; Roy Min; Kevin Shenderov; Takeshi Egawa; David E Levy; Warren J Leonard; Dan R Littman
Journal:  Nat Immunol       Date:  2007-06-20       Impact factor: 25.606

View more
  2 in total

1.  Targeting the mTOR pathway in idiopathic multicentric Castleman disease.

Authors:  Robert M Stern; Nancy Berliner
Journal:  J Clin Invest       Date:  2019-10-01       Impact factor: 14.808

2.  Interleukin-6-producing Intravascular Large B-cell Lymphoma with Lymphadenopathy Mimicking the Histology of Multicentric Castleman Disease.

Authors:  Kohei Shiroshita; Taku Kikuchi; Mikio Okayama; Hidenori Kasahara; Takahiro Kamiya; Takayuki Shimizu; Nozomu Kurose; Yasufumi Masaki; Shinichiro Okamoto
Journal:  Intern Med       Date:  2020-08-04       Impact factor: 1.271

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.